news

CUPERTINO, Calif., Nov. 15, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Stifel 2019 Health Care Conference, at the Lotte New York Palace Hotel on Tuesday, November 19, 2019 at 3:35 p.m. EST.  Institutional investors and analysts that are attending the conference may request […]

Live Webcast of Data Presentation and Discussion by KOL, Tarek I. Hassanein, M.D. at Noon ET on Tuesday, November 12, 2019 CUPERTINO, Calif., Nov. 12, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in alcoholic hepatitis (AH), presented as a late-breaking oral presentation at The Liver

Call will feature data from DURECT’s late-breaking oral presentation at the 2019 Liver Meeting® CUPERTINO, Calif., Nov. 6, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will host a key opinion leader (KOL) conference call and live webcast to discuss the results of its recently completed Phase 2a clinical trial of DUR-928 in

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., Nov. 4, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2019 and provided a corporate update. Total revenues were $10.8 million and net loss was $2.0 million for the three months ended

CUPERTINO, Calif., Oct. 30, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report third quarter and nine months ended September 30, 2019 financial results and host a conference call after the market close on Monday, November 4, 2019. Monday November 4 @ 4:30pmET/1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560 Conference

Study Results Were Selected for Inclusion in the “Best of The Liver Meeting” Summary Slide Presentation Poster Comparing DUR-928 Data to Historical Control Will Also be Presented CUPERTINO, Calif., Oct. 21, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that the results from the recently completed Phase 2a study of DUR-928 in patients with alcoholic

CUPERTINO, Calif., Oct. 17, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will be presenting at two upcoming investor conferences focused on non-alcoholic steatohepatitis (NASH): the H.C. Wainwright 3rd Annual NASH Investor Conference, to be held in New York City on Monday, October 21, 2019 and the B. Riley “NASH-ing in, Let’s All Dig

  CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis. The company also announced that it has now enrolled 30 of the planned 60 patients in its ongoing Phase 1b trial

  CUPERTINO, Calif., Oct. 2, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR® (bupivacaine extended-release solution) will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). The meeting is

  CUPERTINO, Calif., Sept. 26, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference, at the InterContinental New York Barclay Hotel on Friday, October 4, 2019 at 10:40 a.m. EDT.  Institutional investors and analysts that are attending the